Generally, in today’s time, we are hearing more news about the failure of two major organs — one is the liver and the other is the heart.
If you want to get more information about the liver, then from the links given — https://manbik.com/liver-function-test/, https://manbik.com/liver-cirrhosis/, and https://manbik.com/how-to-keep-the-liver-protected/ — you will get complete information about the liver
Just as we do a Liver Function Test to get information about the liver and to know its condition, similarly, to get information about the heart, we do a Lipid Profile Test.
Through the Lipid Profile Test, we get information not only about the heart but also about the condition of the blood vessels.”
Lipid Profile
| Test Name | Unit | Bio Ref Interval | Method |
| Cholesterol- Total | Mg/dL | Low (Desirable):<200mg/dL, Moderate (Border line) -200-239 mg/dL High: >/=240 mg/dL | Enzymatic |
| Triglycerides | Mg/dL | Normal:<150, Borderline:150-199, High-200-499 Very High>=500 | Glycerol Phosphate Oxide |
| Cholesterol- HDL | Mg/dL | High Risk< 40 mg/dL Low Risk>=40 mg/dL | Accelerator Selective Detergent |
| Cholesterol- LDL | Mg/dL | Desirable:<100, Above desirable :100-129 Border line High: 130-159 High: 160-189 Very High: >=190 | Liquid Selective Detergent |
| Cholesterol- VLDL | Mg/dL | <30 | Calculated |
| Cholesterol: HDL Cholesterol | Ratio | Desirable: 3.5-4.5, High risk :>5 | Calculated |
| LDL: HDL Cholesterol | Ratio | Desirable: 2.5-3.0, High risk :>3.5 | Calculated |
| Non HDL Cholesterol | Mg/dL | Desirable:<130, Above desirable <130-159 Border line High: 160-189 High: 190-219 Very High: >=220 | Calculated |
All the tests listed in this table are included in your Lipid Profile Test. After this test, you will know what the condition of your heart is. If you want more information about cholesterol, you can get it from the link provided: https://manbik.com/the-cholesterol/.
•Lipid results show analytical and biological variation; repeat testing may be recommended before diagnosis or treatment
decisions.
•Indians lie at high risk of developing early (a decade earlier than western populations) and more severe cardiovascular
disease (ASCVD); higher mortality. Dyslipidemia (abnormal lipid profile) affects nearly 80% of population.
•Total cholesterol is the sum of all cholesterol in the blood, including HDL, LDL, VLDL, and remnants.
•LDL Cholesterol (LDL-C), is the main “bad” cholesterol that contributes to plaque buildup, increasing the risk of heart disease
and stroke, typically calculated by the Friedewald formula. Direct LDL-C measurement by homogeneous enzymatic assays
carried out when triglycerides >400 mg/dL or dysbetalipoproteinemia.
•High-density lipoprotein (HDL) or “good” cholesterol is anti-atherogenic (protective). Low HDL-C is a cardiovascular risk
factor; seen in almost two-third of Indians. Values above 60 mg/dl are considered protective.
•Triglyceride (TG) are a key driver of CVD. Indians are especially prone to atherogenic dyslipidemia—high TG, low HDL-C, and
high LDL-C—closely linked to diabetes, metabolic syndrome, and insulin resistance; making TG management crucial.
•Non-HDL-Cholesterol (non-HDL-C) Non-HDL-C measures all plaque-forming lipoproteins and is vital to monitor in high-TG
patients (e.g., diabetics, obese) and those on statin therapy.
•Lipid Association of India (LAI-2020) recommends:-
Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Major Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age
(<55 yrs in males, <65 yrs in female or before menopause), current smoking/tobacco use, High blood pressure, Low HDL
(males <40 mg/dl and females <50mg/dl).
Fasting not mandatory; both fasting and non-fasting lipid profiles are useful for screening in Indian patients.
LAI identifies both LDL-C and non-HDL-C as risk factors and recommends LDL-C, non-HDL-C and Apo-B as targets of lipidlowering
therapy.
Lifestyle changes are the first-line approach for managing and preventing dyslipidemia. Treatment in low-risk individuals is
initiated only after 3 months of unsuccessful lifestyle modification.
Testing for Apolipoprotein B(Apo-B), hsCRP, Lp(a ) should be considered for patients in moderate risk group.
